Product Images Cangrelor
View Photos of Packaging, Labels & Appearance
- cangrelor-spl-carton-label - cangrelor spl carton label
- cangrelor-spl-container-label - cangrelor spl container label
- cangrelor-spl-figure-1 - cangrelor spl figure 1
- cangrelor-spl-figure-2 - cangrelor spl figure 2
- cangrelor-spl-figure-3 - cangrelor spl figure 3
- cangrelor-spl-figure-4 - cangrelor spl figure 4
- cangrelor-spl-structure - cangrelor spl structure
Product Label Images
The following 7 images provide visual information about the product associated with Cangrelor NDC 68083-412 by Gland Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
cangrelor-spl-carton-label - cangrelor spl carton label
This text provides information about a medical product called Cangrelor for Injection. It elaborates on the dosage, storage, reconstitution process, manufacturer details, and packing specifications. The product is intended for intravenous use and must be reconstituted and diluted before administration. It includes details such as the amount of cangrelor per vial, the composition, and the reconstitution process. It also mentions the specific conditions for storage and instructions for use.*
cangrelor-spl-container-label - cangrelor spl container label
cangrelor-spl-figure-1 - cangrelor spl figure 1
cangrelor-spl-figure-2 - cangrelor spl figure 2
This is the chart showing the Pharmacodynamic (PD) characteristics of Cangrelor over time when administered at an infusion rate of 4 meg/kg/min. The chart displays the effects of Cangrelor on various parameters such as recovery time, platelet aggregation, and other factors over a 160-minute period. The data points present information on how Cangrelor influences these characteristics throughout the duration of the infusion.*
cangrelor-spl-figure-3 - cangrelor spl figure 3
This text provides information about the inhibition of ADP-induced platelet aggregation by cangrelor based on a study using light transmission aggregometry. It includes details of the dosages administered and the measurement of platelet aggregation after cangrelor infusion. The text mentions transitioning to other oral P2Y12 platelet inhibitors after the infusion.*
cangrelor-spl-figure-4 - cangrelor spl figure 4
cangrelor-spl-structure - cangrelor spl structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
